Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates

The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform

Philips unveils AI-powered SmartIQ to enhance coronary imaging

New CE-marked algorithm for the Azurion platform delivers improved image quality with over 50% lower radiation dose compared to the lowest settings on ClarityIQ

Shaily gets regulatory nod for launch of ShailyPen Neo device technology

The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval

Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats

IGI’s new drug candidate ISB 2301 to target solid tumors

The company intends to file an IND submission by the end of this year and begin clinical studies in 2027

Bayer’s NUBEQA combo shows 71% drop in risk of progression or death in prostate cancer trial

Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm

India’s opportunity to build preventive healthcare economy

The country’s strength lies not just in technology availability but in adoption behaviour

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

ParexelAI launched to accelerate clinical development and improve trial efficiency

The platform combines internally developed technologies, strategic partnerships, and external AI capabilities